Editorials
Subgroups Within “Nonspecific” Low Back Pain
G. Waddell ........................................395

Thrombosis and Inflammation: A Question in Need of an Answer
R. Bobba, C. Landolt-Marticorena, P.R. Fortin ..........................397

Phospholipase A\textsubscript{2}: Quo Vadis?
W. Pruzanski .........................................400

Study Eligibility Criteria: The Perils of Feasibility Based Decision Making
A.M. Davis .................................................403

Articles
Osteopontin Gene Polymorphisms in Spanish Patients with RA
E. Urcelay, A. Martínez, A. Mas-Fontao, et al ..........................405

Overexpression of Osteopontin in Rheumatoid Synovial Mononuclear Cells Is Associated with Joint Inflammation, Not with Genetic Polymorphism
G. Xu, W. Sun, D. He, et al .....................................410

A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial of LY333013, a Selective Inhibitor of Group II Secretory PLA\textsubscript{2}, in the Treatment of RA

Detection of the p53 Regulator Murine Double-Minute Protein 2 in RA
E. Taranto, J.R. Xue, D. Lacey, et al .....................................424

Prediction of Mortality in RA Based on Disease Activity Markers

Traditional and Nontraditional Cardiovascular Risk Factors Are Associated with Atherosclerosis in RA
P.H. Dessein, B.J. Joffe, M.G. Veller, et al .................................435

Valuing a Hypothetical Cure for RA Using the Contingent Valuation Methodology: The Patient Perspective
B. Fautrel, A.E. Clarke, F. Guillemín, et al .................................443

Studies of Serum CRP in SLE
R.C. Williams Jr, M.E. Harmon, R. Burlingame, T.W. Du Clos ........................................454

Inflammation in Patients with Lupus Anticoagulant and Implications for Thrombosis
T. Sailer, R. Vormittag, I. Pabinger, et al .....................................462

Antiinflammatory Effect of A3 Adenosine Receptor Agonists in Murine Autoimmune Arthritis Models
E. Baharav, S. Bar-Yehuda, L. Madi, et al .....................................469

The Cytoplasmic Dot Staining Pattern Is Detected in a Subgroup of Patients with Primary Biliary Cirrhosis

CNS Involvement in Hepatitis C Virus
Cryoglobulinemia Vasculitis: A Multicenter Case-Control Study Using MRI and Neuropsychological Tests
M. Casato, D. Saadoun, A. Marchetti, et al .................................484

Absence of Cyclic Citrullinated Peptide Antibody in Nonarthritic Patients with Chronic Hepatitis C Infection
D. Lienesch, R. Morris, A. Metzger, P. Debuys, K. Sherman ..................489

Patients with SSC Have Unique and Persistent Alterations in Gastric Myoelectrical Activity with Acupressure to Neiguan Point PC6
D.E. Wollaston, X. Xu, O. Tokumaru, J.D.Z. Chen, T.A. McNearney ..................494

Ischemic Heart Disease in Patients from Northwest Spain with Biopsy Proven GCA. A Population Based Study

MCP-1 Gene Haplotype Association in Biopsy Proven GCA
M.M. Amoli, F. Salway, E. Zeggini, W.E.R. Ollier, M.A. Gonzalez-Gay ........................................507

Antibodies to Cyclic Citrullinated Peptides in PsA
L. Bogiolo, C. Alpini, R. Caporali, C.A. Scirè, R. Moratti, C. Montecucco ........................................511

Impact of Functional Impairment in AS: Impairment, Activity Limitation, and Participation Restrictions
H. Dagfinrud, I. Kjeken, P. Mowinckel, K.B. Hagen, T.K. Kvien ........................................516

Reactive Joint Symptoms Following an Outbreak of Salmonella typhimurium Phage Type 135a
A.T.Y. Lee, R.G. Hall, K.D. Pile ...........................................524

Epidemiological Differences Between Back Pain of Sudden and Gradual Onset
J. Smedley, H. Inskip, P. Buckle, C. Cooper, D. Coggan ........................................528

Patient Preference in a Crossover Clinical Trial of Patients with OA of the Knee or Hip: Face Validity of Self-Report Questionnaire Ratings
T. Pincus, X. Wang, C. Chung, T. Sokka, G.G. Koch ........................................533

Contents continued on page vi
What WOMAC Pain Score Should Make a Patient Eligible for a Trial in Knee OA?  
J. Goggins, K. Baker, D. Felson ...............................540

Self-Management in OA of Hip or Knee: A Randomized Clinical Trial in a Primary Healthcare Setting  
P.H.T.G. Heuts, R. de Bie, M. Drietelaar, et al ..........543

Fracture Prevalence and Treatment with Bone-Sparing Agents: Are There Urban-Rural Differences? A Population Based Study in Ontario, Canada  
S.M. Cadarette, S.B. Jaglal, G.A. Hawker .................550

Pediatric Rheumatology
Evaluation of Revised ILAR Classification Criteria for JIA in Spanish Children (Edmonton 2001)  
R. Merino, J. De Inocencio, J. García-Consuegra ....559

Case Reports
Two Cases of ANA Negative Lupus Showing Increased Proportion of B Cells Lacking RP105  
S. Koarada, M. Ide, Y. Haruta, et al ......................562

Multicentric Reticulohistiocytosis Responding to TNF-α Inhibition in a Renal Transplant Patient  
S.E. Shannon, H.R. Schumacher, S. Self, A.N. Brown ........................................565

Correspondence
Trial of Tramadol/Acetaminophen Tablets for OA Pain in Subjects Receiving a COX-2 NSAID  
M.H. Ellman, J. Curran .................................568
Reply R. Emkey ........................................568

Book Review
Low Back and Neck Pain: Comprehensive Diagnosis and Management ........................................569

Correction
Chronic Back Pain: Searching for Causes and Cures  
J.H. Atkinson ........................................569

Meetings in Rheumatology